Shopping Cart
- Remove All
Your shopping cart is currently empty
NFATc1-IN-1
NFATc1-IN-1 (also known as compound A04) is a highly effective inhibitor of osteoclast formation induced by RANKL, with an IC50 of 1.57 μM. It exerts its anti-osteoclastogenic effects by attenuating the RANKL-induced nuclear translocation of NFATc1. Due to its remarkable properties, NFATc1-IN-1 holds significant potential for advancing research related to osteoclastic diseases [1].
Catalog No. T61531Cas No. 1912422-56-0
Select Batch
Purity:99.64%
Contact us for more batch information
NFATc1-IN-1
Catalog No. T61531Cas No. 1912422-56-0
NFATc1-IN-1 (also known as compound A04) is a highly effective inhibitor of osteoclast formation induced by RANKL, with an IC50 of 1.57 μM. It exerts its anti-osteoclastogenic effects by attenuating the RANKL-induced nuclear translocation of NFATc1. Due to its remarkable properties, NFATc1-IN-1 holds significant potential for advancing research related to osteoclastic diseases [1].
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose. | Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 5 mg | $47 | In Stock | |
| 10 mg | $80 | In Stock | |
| 25 mg | $163 | In Stock | |
| 50 mg | $247 | In Stock | |
| 100 mg | $372 | In Stock | |
| 500 mg | $869 | In Stock |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "NFATc1-IN-1"
Alisol B
T577018649-93-9
Alisol B may be a potential novel therapeutic molecule for bone disorders through targeting the differentiation of osteoclasts as well as their functions. Alisol B also inhibited RANKL-induced expression of NFATc1 and c-Fos, which are key transcription factors for osteoclastogenesis.
- $64
Size
QTY
Boldine
ex Peumus boldus, 1,10-Dimethoxy-2,9-dihydroxyaporphine
T5720476-70-0
Boldine (1,10-Dimethoxy-2,9-dihydroxyaporphine) is a natual product .Boldine displays anti-cancer, cytoprotective , anti-oxidant and anti-inflammatory activities.
- $35
Size
QTY
Denosumab
T9917615258-40-7
Denosumab is a monoclonal antibody given subcutaneously that inhibits osteoclast activity by targeting the RANK ligand
- $178
Size
QTY
Narlumosbart
T806182646587-68-8
Narlumosbart (JMT103) is an IgG4κ monoclonal antibody that selectively binds to the receptor activator of nuclear factor-κB ligand (RANKL)[1].
- Inquiry Price
Size
QTY
Product Introduction
Bioactivity
Chemical Properties
| Description | NFATc1-IN-1 (also known as compound A04) is a highly effective inhibitor of osteoclast formation induced by RANKL, with an IC50 of 1.57 μM. It exerts its anti-osteoclastogenic effects by attenuating the RANKL-induced nuclear translocation of NFATc1. Due to its remarkable properties, NFATc1-IN-1 holds significant potential for advancing research related to osteoclastic diseases [1]. |
| Targets&IC50 | Osteoclast:1.57 μM |
| In vitro | NFATc1-IN-1 (0、0.5、1.0、1.5、2.0、2.5 μM, 4 days) exhibits potent inhibitory activities on osteoclast formation and function, which eventually translates into decreased bone resorption while showing no cytotoxic effects towards osteoclast precursor cells at concentrations of as high as 2.5 μM.[1] NFATc1-IN-1 (1.5-2.5 μM, 24 h) blocks NFATc1 nuclear translocation and decreases the level of NFATc1.[1] |
| Molecular Weight | 375.11 |
| Formula | C13H8F2INO2 |
| Cas No. | 1912422-56-0 |
Storage & Solubility Information
| Storage | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 112.5 mg/mL (299.9 mM ), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy NFATc1-IN-1 | purchase NFATc1-IN-1 | NFATc1-IN-1 cost | order NFATc1-IN-1 | NFATc1-IN-1 chemical structure | NFATc1-IN-1 in vitro | NFATc1-IN-1 formula | NFATc1-IN-1 molecular weight
- TOP
Feedback
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.